Healthcare provider profile · identity verified

Kurt Olaveson

Family Practice · SOUTH OGDEN, UT · NPI 1508278615

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	608	163
Omeprazole	Omeprazole	462	120
Losartan Potassium	Losartan Potassium	388	111
Amlodipine Besylate	Amlodipine Besylate	346	102
Levothyroxine Sodium	Levothyroxine Sodium	322	66
Lisinopril	Lisinopril	246	75
Metformin Hcl	Metformin Hcl	241	44
Hydrochlorothiazide	Hydrochlorothiazide	201	66
Metoprolol Succinate	Metoprolol Succinate	193	58
Gabapentin	Gabapentin	183	58
Tamsulosin Hcl	Tamsulosin Hcl	182	53
Pantoprazole Sodium	Pantoprazole Sodium	180	34
Metformin Hcl Er	Metformin Hcl	124	35
Alendronate Sodium	Alendronate Sodium	122	38
Furosemide	Furosemide	114	32
Eliquis	Apixaban	113	21
Fluoxetine Hcl	Fluoxetine Hcl	101	30
Fluticasone Propionate	Fluticasone Propionate	100	48
Celecoxib	Celecoxib	99	34
Prednisone	Prednisone	98	44
Albuterol Sulfate Hfa	Albuterol Sulfate	96	32
Glipizide Er	Glipizide	96	18
Allopurinol	Allopurinol	94	22
Metoprolol Tartrate	Metoprolol Tartrate	90	22
Xarelto	Rivaroxaban	90	20
Trazodone Hcl	Trazodone Hcl	88	25
Citalopram Hbr	Citalopram Hydrobromide	85	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	81	21
Simvastatin	Simvastatin	81	23
Potassium Chloride	Potassium Chloride	72	22
Sertraline Hcl	Sertraline Hcl	72	17
Carvedilol	Carvedilol	71	19
Rosuvastatin Calcium	Rosuvastatin Calcium	71	27
Zolpidem Tartrate	Zolpidem Tartrate	66	13
Montelukast Sodium	Montelukast Sodium	64	17
Duloxetine Hcl	Duloxetine Hcl	62	21
Pioglitazone Hcl	Pioglitazone Hcl	58	16
Quetiapine Fumarate	Quetiapine Fumarate	56	14
Loperamide	Loperamide Hcl	54	suppressed
Finasteride	Finasteride	52	17
Pravastatin Sodium	Pravastatin Sodium	52	15
Trulicity	Dulaglutide	51	suppressed
Bupropion Xl	Bupropion Hcl	49	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	49	13
Pregabalin	Pregabalin	49	suppressed
Jardiance	Empagliflozin	46	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	45	11
Ropinirole Hcl	Ropinirole Hcl	44	suppressed
Ozempic	Semaglutide	43	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	41	14
Ezetimibe	Ezetimibe	40	13
Meloxicam	Meloxicam	40	17
Clopidogrel	Clopidogrel Bisulfate	39	11
Chlorthalidone	Chlorthalidone	38	12
Lorazepam	Lorazepam	38	suppressed
Alprazolam	Alprazolam	37	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	35	11
Lantus	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	33	suppressed
Spironolactone	Spironolactone	32	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Benazepril Hcl	Benazepril Hcl	29	suppressed
Valacyclovir	Valacyclovir Hcl	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Levetiracetam	Levetiracetam	27	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Fenofibrate	Fenofibrate	26	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Amoxicillin	Amoxicillin	25	23
Enalapril Maleate	Enalapril Maleate	25	suppressed
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	24	24
Glimepiride	Glimepiride	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	19
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	17
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Irbesartan	Irbesartan	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	17
Synthroid	Levothyroxine Sodium	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Clonazepam	Clonazepam	19	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Modafinil	Modafinil	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Famotidine	Famotidine	15	suppressed
Fluconazole	Fluconazole	15	suppressed
Verapamil Sr	Verapamil Hcl	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Cephalexin	Cephalexin	14	12
Divalproex Sodium	Divalproex Sodium	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Risperidone	Risperidone	13	suppressed
Tramadol Hcl	Tramadol Hcl	13	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Cefuroxime	Cefuroxime Axetil	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Portia	Levonorgestrel/Ethin.Estradiol	12	suppressed
Creon	Lipase/Protease/Amylase	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Levemir Flexpen	Insulin Detemir	11	suppressed
Olanzapine	Olanzapine	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error